Connect Biopharma Holdings Limited Ordinary Shares CNTB
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-11T05:55:04.050Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-10T23:27:30.946453209Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-11T05:55:03.719436+00:00
Connect Biopharma Holdings Limited Ordinary Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 2.30 | 561.5% | 250.8% | 0.54 | 795.0% | 95.0% |
| 25Δ | 2.18 | 598.7% | 241.2% | 0.66 | 778.8% | 79.0% |
| 30Δ | 2.05 | 635.8% | 231.7% | 0.78 | 762.6% | 63.0% |
| 35Δ | 1.93 | 673.0% | 222.2% | 0.91 | 746.4% | 46.9% |
| 40Δ | 1.80 | 710.2% | 212.6% | |||
| 45Δ | 1.68 | 747.3% | 203.1% | |||
| 50Δ | 1.55 | 784.5% | 193.6% | |||
| 55Δ | 1.38 | 800.0% | 172.2% | |||
| 60Δ | 1.17 | 800.0% | 142.4% | |||
| 65Δ | 0.98 | 800.0% | 114.0% | |||
| 70Δ | 0.83 | 800.0% | 93.1% | |||
| 75Δ | 0.69 | 800.0% | 72.2% | |||
| 80Δ | 0.54 | 800.0% | 51.3% | |||
20Δ
- Pseudo strike
- 2.30
- IV
- 561.5%
- B/E move
- 250.8%
- Pseudo strike
- 0.54
- IV
- 795.0%
- B/E move
- 95.0%
25Δ
- Pseudo strike
- 2.18
- IV
- 598.7%
- B/E move
- 241.2%
- Pseudo strike
- 0.66
- IV
- 778.8%
- B/E move
- 79.0%
30Δ
- Pseudo strike
- 2.05
- IV
- 635.8%
- B/E move
- 231.7%
- Pseudo strike
- 0.78
- IV
- 762.6%
- B/E move
- 63.0%
35Δ
- Pseudo strike
- 1.93
- IV
- 673.0%
- B/E move
- 222.2%
- Pseudo strike
- 0.91
- IV
- 746.4%
- B/E move
- 46.9%
40Δ
- Pseudo strike
- 1.80
- IV
- 710.2%
- B/E move
- 212.6%
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- 1.68
- IV
- 747.3%
- B/E move
- 203.1%
- Pseudo strike
- IV
- B/E move
50Δ
- Pseudo strike
- 1.55
- IV
- 784.5%
- B/E move
- 193.6%
- Pseudo strike
- IV
- B/E move
55Δ
- Pseudo strike
- 1.38
- IV
- 800.0%
- B/E move
- 172.2%
- Pseudo strike
- IV
- B/E move
60Δ
- Pseudo strike
- 1.17
- IV
- 800.0%
- B/E move
- 142.4%
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- 0.98
- IV
- 800.0%
- B/E move
- 114.0%
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- 0.83
- IV
- 800.0%
- B/E move
- 93.1%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- 0.69
- IV
- 800.0%
- B/E move
- 72.2%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 0.54
- IV
- 800.0%
- B/E move
- 51.3%
- Pseudo strike
- IV
- B/E move
Options history
No recorded observations
Biotechnology
COGT
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases. The company is headquartered in Cambridge,…
More →CORT
Corcept Therapeutics Incorporated discovers, develops, and markets drugs for the treatment of severe metabolic, cancer, and psychiatric disorders in the United States. The company…
More →COYA
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company is…
More →CRBP
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapies that target the endocannabinoid…
More →CRBU
Caribou Biosciences Inc. is a pioneering biotechnology firm specializing in genome editing through its proprietary CRISPR technology, aimed at developing transformative therapies…
More →CRDF
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. The company is headquartered in San Diego, California.
More →